WaferGen Bio Story

WaferGen Bio systems Inc -- USA Stock  

USD 6.9  0.00  0.00%

Macroaxis does not monitor all media channels or aggregates social signals for WaferGen Bio. But even though we do not provide professional-grade financial sentiment analysis on WaferGen Bio systems, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for WaferGen Bio. See also Your Current Watchlist.
Exercise or conversion by Joel Kanter of 1250 shares of WaferGen Bio subject to Rule 16b-3
Filed transaction by Wafergen Biosystems Inc director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

WaferGen Bio systems Inc insider trading alert for exercise of restricted stock units by Joel Kanter, the corporate stakeholder, on October 2, 2017. This event was filed by Wafergen Biosystems Inc with SEC on 2010-12-20. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This story impact on price volatility cannot be determined at this time. Please check this story after some time to allow current data to be analyzed.

Similar stores for WaferGen Bio

a day ago at www.macroaxis.com 
Disposition of 50001 shares by Rolland Carlson of WaferGen Bio subject to Rule 16b-3
Macroaxis News
Filed transaction by Wafergen Biosystems Inc director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
six days ago at www.macroaxis.com 
Disposition of 8617 shares by Joel Kanter of WaferGen Bio subject to Rule 16b-3
Macroaxis News
Filed transaction by Wafergen Biosystems Inc director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
over a week ago at www.macroaxis.com 
Disposition of 12740 shares by Davidson Scott Richard of WaferGen Bio subject to Rule 16b-3
Macroaxis News
Filed transaction by Wafergen Biosystems Inc director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
over two weeks ago at www.macroaxis.com 
Acquisition by Shivji Alnoor of 150000 shares of WaferGen Bio subject to Rule 16b-3
Macroaxis News
Filed transaction by Wafergen Biosystems Inc director. Grant, award or other acquisition pursuant to Rule 16b-3

Did you try this?

Run Piotroski F Score Now
   

Piotroski F Score

Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Hide  View All  Next  Launch Piotroski F Score

Current Asset

Current Asset Comparative Analysis
  Current Asset 
      WaferGen Bio Comparables 
WaferGen Bio is currently under evaluation in current asset category among related companies. Current Asset is all of company's assets that can be used to pay off current liabilities within current fiscal period or over next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.